Glycomet is an oral antidiabetic medication that contains the active ingredient metformin. It is prescribed to lower blood glucose levels in people with type 2 diabetes mellitus. The drug works by reducing the amount of glucose produced by the liver during fasting. It also enhances the ability of muscle and fat tissue to take up glucose from the bloodstream in response to insulin. This action decreases insulin resistance and promotes more efficient use of glucose by peripheral tissues. As a result overall concentration of sugar in the blood is lowered and sustained at a healthier level. The primary pharmacological effect of metformin therefore stems from these combined alterations in hepatic glucose output and peripheral insulin sensitivity.

Glycomet is an oral antihyperglycemic medication used primarily in the management of type 2 diabetes mellitus. Its pharmacological properties include enhancing insulin sensitivity and reducing hepatic glucose production. The drug acts by activating amp-activated protein kinase in liver and muscle cells which leads to decreased gluconeogenesis and increased peripheral glucose uptake. This activation improves glycemic control by lowering fasting and postprandial blood glucose levels. Glycomet also modestly reduces intestinal absorption of carbohydrates contributing to its overall glucose-lowering effect. The cumulative result is better regulation of blood sugar with a low risk of hypoglycemia when used as monotherapy.

Glycomet may cause gastrointestinal discomfort such as nausea diarrhea and abdominal cramps. It can lead to a metallic taste in the mouth in some users. Some individuals experience skin rashes or itching as an allergic reaction. Rarely it may cause lactic acidosis especially in patients with kidney impairment. The medication can occasionally lower vitamin b12 levels with long term use. Headache and muscle pain have been reported in a small subset of patients. Fatigue and dizziness may occur particularly when treatment is initiated. These effects are generally mild and often improve with continued use.

Glycomet may cause gastrointestinal discomfort such as nausea or diarrhea in some users. Headaches and dizziness are occasionally reported as side effects. Fatigue and muscle pain can occur, especially during the initial phase of treatment. Hypoglycemia is rare but possible when the medication is combined with other glucose-lowering agents. Occasional skin reactions like rash or itching may develop in certain individuals. Rare cases of liver enzyme elevations have been observed in clinical monitoring. Most of these effects are mild and tend to improve with continued use.